Published in Neurosci Lett on July 23, 2009
Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain (2011) 1.50
A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat. Neuroscience (2010) 0.94
APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). Neurosci Biobehav Rev (2012) 0.89
Allopregnanolone and neurogenesis in the nigrostriatal tract. Front Cell Neurosci (2014) 0.83
Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res (2012) 0.82
Dissecting Alzheimer disease in Down syndrome using mouse models. Front Behav Neurosci (2015) 0.79
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science (2010) 3.98
Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science (2008) 3.59
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci (2004) 3.09
Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci (2009) 2.85
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci (2003) 2.84
In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol (2005) 2.81
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A (2006) 2.66
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A (2009) 2.27
Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci (2003) 2.24
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem (2005) 2.12
A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol (2004) 2.09
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord (2006) 2.04
Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci (2005) 1.94
Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res (2002) 1.91
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol (2007) 1.90
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci (2007) 1.85
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol (2007) 1.77
Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog. [corrected]. Cell Stem Cell (2013) 1.77
Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis (2007) 1.77
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging (2007) 1.72
Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci (2002) 1.72
Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res (2006) 1.70
Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med (2008) 1.68
Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci U S A (2005) 1.67
Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease. Biol Psychiatry (2006) 1.66
Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition. J Neurosci (2011) 1.66
No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain (2007) 1.63
App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci (2003) 1.59
Relationship between outcome and baseline blood pressure and other haemodynamic measures in acute ischaemic stroke: data from the TAIST trial. J Hypertens (2006) 1.58
Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro (2010) 1.58
Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2012) 1.58
A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat (2013) 1.53
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A (2003) 1.46
Cystatin C modulates cerebral beta-amyloidosis. Nat Genet (2007) 1.42
Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.42
Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord (2007) 1.38
Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem (2006) 1.37
Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One (2010) 1.37
Molecular imaging of amyloid beta peptides in mouse brain sections using mass spectrometry. Anal Biochem (2002) 1.37
Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behav Brain Res (2005) 1.36
Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci (2003) 1.36
Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. J Neurosci (2006) 1.35
Therapeutic approaches to Alzheimer's disease. Brain (2006) 1.34
Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Hum Mutat (2008) 1.31
Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke (2007) 1.29
Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci (2008) 1.29
Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci (2006) 1.29
Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther (2008) 1.28
Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther (2009) 1.23
Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem (2002) 1.21
Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke (2010) 1.20
In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci (2011) 1.19
Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J (2011) 1.18
APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry (2002) 1.18
Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers. ASN Neuro (2009) 1.17
Senescent changes in cerebrospinal fluid circulatory physiology and their role in the pathogenesis of normal-tension glaucoma. Am J Ophthalmol (2013) 1.16
Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci (2003) 1.16
Age effects on the regulation of adult hippocampal neurogenesis by physical activity and environmental enrichment in the APP23 mouse model of Alzheimer disease. Hippocampus (2009) 1.15
Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem (2002) 1.14
Compromised hemodynamic response in amyloid precursor protein transgenic mice. J Neurosci (2002) 1.14
Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener (2007) 1.13
Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med (2013) 1.13
Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res (2002) 1.13
Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol (2011) 1.13
Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord (2007) 1.10
Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci (2002) 1.10
Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry (2005) 1.09
Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int (2005) 1.09
Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? Int J Geriatr Psychiatry (2009) 1.09
Serum N-glycan profile shift during human ageing. Exp Gerontol (2010) 1.08
Intracranial pressure fluctuations: a potential risk factor for glaucoma? Acta Ophthalmol (2013) 1.08
Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol Aging (2008) 1.08
Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov (2006) 1.07
Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease. Nat Commun (2012) 1.06
Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. Neurobiol Learn Mem (2005) 1.05
Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation (2009) 1.04
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci (2011) 1.03
Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. J Pathol (2012) 1.03
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry (2005) 1.03
Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. Neurobiol Aging (2006) 1.02
DLB and PDD: a role for mutations in dementia and Parkinson disease genes? Neurobiol Aging (2011) 1.02
Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. Hum Mol Genet (2005) 1.01
Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion. PLoS One (2009) 1.01
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. Ann Neurol (2002) 1.01
Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res (2002) 1.00
Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol Aging (2005) 1.00